" Early February we started the development of a rapid antigen detection assay for SARS-CoV-2. The COVID-19 Ag Respi-Strip Assay was validated in three University hospital laboratories and registered (CE mark) by end of March. The test is designed as a first line triage assay to be used for rapid (15 minutes) detection of SARS-CoV-2 on symptomatic patients. We are currently developing a serological assay that targets the immune response against several antigens of the virus. "
Publication References: https://jcm.asm.org/content/jcm/early/2020/05/11/JCM.00977-20.full.pdf https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?utm_campaign=ba-cov-sci-fmed-respi-strip&utm_medium=cvlp&utm_source=fweb
Pascal Mertens, R&D Director